Prosecution Insights
Last updated: October 02, 2026

Examiner: PERREIRA, MELISSA JEAN

Tech Center 1600 • Art Units: 1618

This examiner grants 52% of resolved cases

Analysis

Melissa Jean Perreira is an examiner in Art Unit 1618 within Tech Center 1600. The examiner has 836 resolved cases and an allowance rate of 52.0 percent. This rate indicates a balanced outcome for applications in this unit. The examiner's record provides a basis for understanding prosecution trends in this unit.

The interview lift is 25.8 percent, which indicates that conducting an interview significantly increases the probability of allowance compared to the baseline rate of 52.0 percent. This is a strong recommendation for practitioners to engage with the examiner directly. For applications that reach allowance, the median time to allowance is 1375 days. This pendency figure provides a timeline for the expected duration of prosecution.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

52.0%
Allow Rate
-8.0% vs TC avg
877
Total Applications
+25.8%
Interview Lift
1375
Avg Prosecution Days
Based on 836 resolved cases, 2023–2026

Rejection Statute Breakdown

2.0%
§101 Eligibility
12.7%
§102 Novelty
56.1%
§103 Obviousness
16.5%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16400922 Pharmaceutical Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes Final Rejection Intuitive Surgical Operations, Inc.
18080346 METHODS AND MATERIALS FOR TREATING HYPOCAPNIA Final Rejection Mayo Foundation for Medical Education and Research
18990863 IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) Final Rejection The Johns Hopkins University
18052804 PSMA-TARGETING COMPOUNDS AND USES THEREOF Non-Final OA The Johns Hopkins University
17040967 METHODS AND ASSAYS FOR MODULATING GENE TRANSCRIPTION BY MODULATING CONDENSATES Final Rejection Massachusetts Institute of Technology
19240908 METHOD OF TREATING PROSTATE CANCER Non-Final OA Novartis AG
17542358 PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION Non-Final OA HOFFMANN-LA ROCHE INC.
18969629 Stable Soft Chews, and Methods to Produce Same Non-Final OA Florida Research Group, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month